Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Godi

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The Journal of Infectious Diseases|August 15, 2019
Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine AntibodiesAnna Godi, Troy J Kemp, Ligia A Pinto, et al.
Vaccine|January 21, 2014
Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificitiesSara L Bissett, Eve Draper, Richard E Myers, et al.
Current Biology : CB|October 7, 2008
DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cellsGilles Gadea, Victoria Sanz-Moreno, Annette Self, et al.
Journal of Virology|January 1, 2016
Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV VaccinesAnna Godi, Alessandra Facchetti, Sara L Bissett, et al.
The Journal of General Virology|March 15, 2015
Amino acid motifs in both the major and minor capsid proteins of HPV51 impact antigenicity and infectivityAnna Godi, Ilaria Epifano, Sara L Bissett, et al.
Journal of Virology|May 22, 2015
Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 SerotypeSara L Bissett, Anna Godi, Maxime J J Fleury, et al.
Methodsx|July 11, 2022
Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assayKavita Panwar, Anna Godi, Clementina E Cocuzza, et al.
Vaccine|February 4, 2022
Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccineKavita Panwar, Anna Godi, Clementina E Cocuzza, et al.
The Journal of Infectious Diseases|June 16, 2018
Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing AntibodiesAnna Godi, Marianna Martinelli, Mahmoud Haque, et al.
Vaccine|September 10, 2014
Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteinsSara L Bissett, Giada Mattiuzzo, Eve Draper, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The Journal of Infectious Diseases|August 15, 2019
Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine AntibodiesAnna Godi, Troy J Kemp, Ligia A Pinto, et al.
Vaccine|January 21, 2014
Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificitiesSara L Bissett, Eve Draper, Richard E Myers, et al.
Current Biology : CB|October 7, 2008
DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cellsGilles Gadea, Victoria Sanz-Moreno, Annette Self, et al.
Journal of Virology|January 1, 2016
Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV VaccinesAnna Godi, Alessandra Facchetti, Sara L Bissett, et al.
The Journal of General Virology|March 15, 2015
Amino acid motifs in both the major and minor capsid proteins of HPV51 impact antigenicity and infectivityAnna Godi, Ilaria Epifano, Sara L Bissett, et al.
Journal of Virology|May 22, 2015
Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 SerotypeSara L Bissett, Anna Godi, Maxime J J Fleury, et al.
Methodsx|July 11, 2022
Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assayKavita Panwar, Anna Godi, Clementina E Cocuzza, et al.
Vaccine|February 4, 2022
Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccineKavita Panwar, Anna Godi, Clementina E Cocuzza, et al.
The Journal of Infectious Diseases|June 16, 2018
Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing AntibodiesAnna Godi, Marianna Martinelli, Mahmoud Haque, et al.
Vaccine|September 10, 2014
Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteinsSara L Bissett, Giada Mattiuzzo, Eve Draper, et al.
Pageof 3